Q1 EPS Forecast for CRISPR Therapeutics Decreased by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) – Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of ($1.60) for the quarter, down from their prior forecast of ($1.51). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.65) EPS, Q3 2025 earnings at ($1.54) EPS, Q4 2025 earnings at ($1.60) EPS, FY2025 earnings at ($6.39) EPS, Q1 2026 earnings at ($1.82) EPS, Q2 2026 earnings at ($1.67) EPS, Q3 2026 earnings at ($1.35) EPS, Q4 2026 earnings at ($1.32) EPS and FY2026 earnings at ($6.16) EPS.

Several other equities research analysts also recently issued reports on CRSP. HC Wainwright assumed coverage on shares of CRISPR Therapeutics in a research note on Monday, February 3rd. They set a “buy” rating and a $65.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, January 14th. Royal Bank of Canada reissued a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Barclays lowered their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Finally, StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $77.59.

CRISPR Therapeutics Price Performance

NASDAQ CRSP opened at $39.62 on Monday. The business’s 50-day simple moving average is $42.45 and its 200-day simple moving average is $46.40. The firm has a market capitalization of $3.38 billion, a P/E ratio of -14.00 and a beta of 1.67. CRISPR Therapeutics has a 1-year low of $36.52 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%.

Hedge Funds Weigh In On CRISPR Therapeutics

Several large investors have recently made changes to their positions in the business. Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $39,000. Western Pacific Wealth Management LP increased its holdings in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after acquiring an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in CRISPR Therapeutics during the third quarter worth approximately $40,000. Darwin Wealth Management LLC acquired a new position in CRISPR Therapeutics during the third quarter valued at approximately $43,000. Finally, Eastern Bank acquired a new position in CRISPR Therapeutics in the 3rd quarter valued at $70,000. Institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.